VVM
Versant Venture Management Portfolio holdings
AUM
$141M
1-Year Est. Return
190.82%
This Fund
S&P 500
1 Year Est. Return
+190.82%
AUM
$141M
AUM Growth
-$9.65M
(-6.4%)
Holding
8
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Monte Rosa Therapeutics
GLUE
$1.63B
| $52.3M | 37% |
3,180,780
-1,201,907
|
|
||
2
Century Therapeutics
IPSC
$422M
| $27.5M | 19.44% |
+12,166,109
|
|
||
|
LENZ
3
LENZ Therapeutics
LENZ
$304M
| $24.3M | 17.19% |
2,656,888
|
|
||
|
JBIO
4
Jade Biosciences
JBIO
$1.24B
| $21.4M | 15.16% |
1,525,820
|
|
||
|
CTNM
5
Contineum Therapeutics
CTNM
$559M
| $7.09M | 5.01% |
542,628
|
|
||
6
CRISPR Therapeutics
CRSP
$5.31B
| $7.08M | 5.01% |
148,831
|
|
||
7
Skye Bioscience
SKYE
$29.9M
| $1.23M | 0.87% |
2,007,704
|
|
||
8
Tempest Therapeutics
TPST
$29M
| $442K | 0.31% |
269,772
|
|